New indications for superficial basal cell carcinoma and adolescent alopecia areata expanded treatment options, while psoriasis and rare disease candidates advanced through FDA review.
News|Articles|October 13, 2026
Social Media Mythbusters: “Botox in a Bottle”
Author(s)Shannon Heaning, Content Associate
Can “Botox in a bottle” really rival injectable neuromodulators? We examine the evidence behind topical peptide serums and Argireline.
Advertisement
Advertisement
From viral skin care hacks to trendy treatment devices, social media is shaping the questions patients bring into the exam room every day. In Dermatology Times’ weekly series, Social Media Mythbusters, we break down trending claims clinicians are hearing in practice—exploring the proposed mechanism, what the evidence shows (or doesn’t), and whether each trend holds up under scrutiny.
Related to this article
Dermatology clinicians at a Case-Based Roundtable in Austin, Texas, discussed real-world strategies for sequencing topical therapy, phototherapy, and ruxolitinib cream across pediatric and adult vitiligo cases.
Christophe Piketty discusses 3-year ARCADIA data demonstrating sustained efficacy and long-term safety of nemolizumab in atopic dermatitis.
Two claims analyses of hidradenitis suppurativa showed similar symptom prevalence in males and females and lower dermatologist access among rural patients than urban patients.
Day 3 of Fall Clinical 2026 featured roflumilast data in genital psoriasis, long-term JAK inhibitor safety in atopic dermatitis, and expert insights on setting expectations in HS, treating advanced cSCC, and screening aesthetic patients.
In a retrospective study of 393 patients, 51.9% had at least 1 abnormal LFT during follow-up, but only 1.1% had elevations above 3 times the upper limit of normal.
Patients with plaque psoriasis treated with roflumilast cream or foam reported greater improvements in sexual function and relationships vs vehicle, including those with genital involvement at baseline.
The second day of Fall Clinical 2026 brought new psoriasis data on ixekizumab plus tirzepatide and 2-year icotrokinra results, along with 3-year nemolizumab findings, upadacitinib switch data, and expert guidance on choosing a biologic in atopic dermatitis.
Advertisement
Advertisement